QTTB

Do not be fooled by the 5.4x P/E and 55.5% net margin. Q32 Bio is a pre-commercial, clinical-stage biotech whose lead candidate bempikibart is still in development — the filing repeatedly discusses 'regulatory and clinical progress of our product candidates,' 'cash runway,' and 'needs for additional financing,' which is not the language of a self-funding, profitable enterprise. The reported FY2025 net income of +$29.8M is almost certainly non-operational: revenue leapt to $53.7M from $0.00 in FY2024 (and negative $6.65M in FY2023), consistent with a one-time collaboration/upfront rather than recurring product sales, and it is flatly contradicted by operating cash flow of -$33.5M. The business consumed cash, it did not generate it.

The real trajectory is retrenchment, not growth. R&D expense collapsed 60.2% to $19.2M under what the 10-K calls a 'strategic restructuring plan, including the reduction in force.' Cash fell 38.1% to $48.3M, total assets shrank 33.1%, and shares outstanding rose 19.9% — existing holders are being diluted while the company cuts its development engine. At a ~$33.5M annual burn, current cash implies roughly 1.5 years of runway before another raise, which the forward-looking statements explicitly flag as a dependency ('our ability to raise capital to fund our operations').